Long-term observation of patients with Multiple Sclerosis and related disorders in Switzerland
Swiss Multiple Sclerosis Cohort-Study: A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
University Hospital, Basel, Switzerland · NCT02433028
This study is tracking patients with Multiple Sclerosis and related disorders in Switzerland to see how their conditions change over time and to gather important health information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland (other) |
| Locations | 8 sites (Aarau, Canton of Aargau and 7 other locations) |
| Trial ID | NCT02433028 on ClinicalTrials.gov |
What this trial studies
The Swiss Multiple Sclerosis Cohort Study is a multicentre observational study involving eight Swiss MS centers aimed at creating a long-term cohort of patients diagnosed with Multiple Sclerosis, neuromyelitis optica spectrum disorder, and Myelin oligodendrocyte glycoprotein antibody-associated disease. The study focuses on systematic follow-up with standardized collection of clinical data, MRI data, and biological samples to better understand the heterogeneity of these conditions. By maintaining high-quality data over an extended period, the study seeks to facilitate research on disease evolution and treatment dynamics.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with various forms of Multiple Sclerosis, neuromyelitis optica spectrum disorder, or Myelin oligodendrocyte glycoprotein antibody-associated disease who are willing to commit to regular hospital visits and blood donations.
Not a fit: Patients who are not diagnosed with the specified conditions or those unable to attend regular follow-up visits may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term progression and treatment of Multiple Sclerosis and related disorders, potentially leading to improved patient outcomes.
How similar studies have performed: Other cohort studies in Multiple Sclerosis have shown success in advancing understanding of the disease, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fulfilling the diagnosis of radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), relapsing-remitting Multiple Sclerosis (RRMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), neuromyelitis optica spectrum disorder (NMOSD) or Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) according to established criteria * Intending to attend hospital visits every 6 months (+/- 45 days) or 12 months (+/- 45 days) (facultative cranial MRI every 12 months) over a longer period (at least 5 years) * Intending to give blood for biobanking every 6 or 12 months during hospital visit or as close as possible to the visit (+/- 8 days) Inclusion criteria are crafted to identify a population of patients with MS, NMOSD or MOGAD particularly suitable for analysing disease evolution and associated factors, treatment dynamics, and the long-term safety and efficacy profile of disease-modifying drugs. There are no specific Exclusion Criteria.
Where this trial is running
Aarau, Canton of Aargau and 7 other locations
- Cantonal Hospital Aarau — Aarau, Canton of Aargau, Switzerland (RECRUITING)
- University Hospital Basel — Basel, Canton of Basel-City, Switzerland (RECRUITING)
- University Hospital Berne — Bern, Canton of Bern, Switzerland (RECRUITING)
- University Hospital Geneva — Geneva, Canton of Geneva, Switzerland (RECRUITING)
- Cantonal Hospital St. Gallen — Sankt Gallen, Canton of St. Gallen, Switzerland (RECRUITING)
- University Hospital Lausanne — Lausanne, Canton of Vaud, Switzerland (RECRUITING)
- Regional Hospital Lugano — Lugano, Canton Ticino, Switzerland (RECRUITING)
- Univeristy Hospital Zürich — Zurich, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Jens Kuhle, MD — University Hospital, Basel, Switzerland
- Study coordinator: Jens Kuhle, MD
- Email: jens.kuhle@usb.ch
- Phone: 0041612652525
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, MS key phases of disease evolution, MS New Treatment Options